Key result
Transthoracic echocardiography guidance during percutaneous PFO closure was successful in all patients, with 0% neurologic or cardiovascular complications over a median 29-month follow-up.
Why the study?
Does transthoracic echocardiography guidance allow safe and effective percutaneous closure of patent foramen ovale?
Observational (n=139)
Does transthoracic echocardiography guidance allow safe and effective percutaneous closure of patent foramen ovale?
TTE guidance during percutaneous PFO closure is safe and effective, potentially obviating the need for transesophageal echocardiography and general anesthesia.
TTE guidance was associated with successful, complication-free PFO closure; leaves open whether it matches TEE safety in randomized trials.
BACKGROUND: Percutaneous closure of patent foramen ovale (PFO) has been increasingly performed for several indications; mostly due to cryptogenic stroke. In this study we aimed to evaluate the safety and efficacy of transthoracic echocardiographic (TTE) guidance during percutaneous closure of PFO in using the Amplatzer and Occlutech Figulla PFO occluder devices. METHODS: Between October 2005 and March 2011, 139 patients (74 male, mean age: 40.4 ± 10.3) underwent transcatheter PFO closure. In all patients transesophageal echocardiography performed subsequently to diagnose, assess the size and evaluate for suitability of the defect for percutaneous closure. During the procedure fluoroscopy and TTE were used for guidance. RESULTS: Among 139 patients, Amplatzer PFO occluder was used in 74 patients and in 65 of them Occlutech Figulla device was selected for occlusion. The indications for PFO closure were ischemic stroke in 98 (70.5%), recurrent transient ischemic attacks (TIA) in 40 (28.7%), peripheral embolism in 1 (0.8%) of the patients. In all patients, percutaneous intervention was performed successfully under TTE guidance. There have been no neurologic (recurrent strokes or TIAs) and cardiovascular complications during the immediate and long-term follow-up period (2-67 months, median 29). There was significant difference between the mean fluoroscopic time from the beginning which is 8.6 ± 3.4 min in the former versus 3.4 ± 1.9 min in the latter (P < 0.05). CONCLUSION: Our study confirms the efficacy and safety of TTE guidance during percutaneous closure of PFO, which shortens the procedural time and obviates the need for general anesthesia or endotracheal intubation.
No takes yet. Share an insight, caveat, or question.
Oto et al. (2011) conducted an observational in Patent foramen ovale (n=139). Transthoracic echocardiography (TTE) guidance was evaluated on Neurologic and cardiovascular complications. Transthoracic echocardiography guidance during percutaneous PFO closure was successful in all patients, with 0% neurologic or cardiovascular complications over a median 29-month follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: